Sun H, Saidi P, Karlanga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: 2021 global, regional, and country diabetes prevalence estimates and 2045 projections. Diabetes Res Clin Pract. 2022;183:109119.
Google Scholar
Olesen KKW, Anand S, Thim T, Gyldenkerne C, Maeng M. Microvascular disease increases the risk of lower extremity amputation: a western Danish cohort study. Eur J Clin Investment 2022;52:e13812.
Google Scholar
Rinkel WD, Luyten J, van Dongen J, Kuppens B, van Neck JW, Polider S, Hospital costs for diabetic foot disease treated by a multidisciplinary foot team. Diabetes treatment clinical practice. 2017;132:68–78.
Google Scholar
Stern JR, Wong CK, Erovinkina M, Spindler SJ, AS Reference, Panjaki S, et al. Meta-analysis of long-term mortality and associated risk factors after lower extremity amputation. Anne Basque Surgeon. 2017;42:322–7.
Google Scholar
Apelqvist J, Larsson J. What is the most effective way to reduce the incidence of diabetic foot amputation? Diabetes Metab Res Rev. 2000;16(Suppl 1):S75–83.
Google Scholar
Eason SL, Petersen NJ, Suarez-Almazor M, Davis B, Collins TC. Diabetes, smoking, and the risk of asymptomatic peripheral artery disease: Who should be tested? J Am Board Femme Pract. 2005;18:355–61.
Google Scholar
Lange S, Diem C, Darius H, Haberle R, Arenberg JR, Pittlow D, et al. High prevalence and low treatment rates of peripheral artery disease in elderly primary care patients with diabetes. Exp Clin Endocrine Diabetes. 2004;112:566–73.
Google Scholar
Murabito JM, D'Agostino RB, Silberschatz H, Wilson WF. Intermittent lameness. Risk profile from the Framingham Heart Study. circulation. 1997;96:44–9.
Google Scholar
American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Care for Diabetes – 2024. diabetes care. 2024;47:S179–218.
Google Scholar
hoi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ et al. 2023 Diabetes Treatment Guidelines of the Korean Diabetes Association. Diabetes Metatab J. 2023;47:575-594
Google Scholar
Yang YS, Kim HL, Kim SH, Moon MK. Lipid management in Korean patients with type 2 diabetes: Consensus statement of the Korean Diabetes Association and the Korean Society of Lipid and Atherosclerosis. Diabetes Metatab J. 2023;47:1–9.
Google Scholar
Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, Cushman M et al. Residual risk of atherosclerotic cardiovascular disease in statin-treated adults: the Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol. 2017;11:1223–33.
Google Scholar
Alsheikh Ali AA, Lin JL, Abuljairi P, Ahern D, Kubin JT, Karas RH. Prevalence of low-density lipoprotein cholesterol in patients with coronary heart disease or equivalent risk and with proven controlled low-density lipoprotein cholesterol. This is J Cardiol. 2007;100:1499–501.
Google Scholar
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Furchert JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Eng J Med 2005;352:1425–35.
Google Scholar
Matfin G, Thorne M. Disagreement on ACCORD-lipid test results. Advanced endocrine meta tab. 2010;1:47–9.
Google Scholar
Shin IM, Shishebolu MH, Ansel BJ. High-density lipoproteins as therapeutic targets: a systematic review. jam. 2007;298:786–98.
Google Scholar
Rubins HB, Robbins SJ, Collins D, Fai CL, Anderson JW, Elam MB, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol levels. Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Research Group. N Eng J Med 1999;341:410–8.
Google Scholar
Flick MH, Erro O, Harpa K, Heinonen OP, Heinsalmi P, Herro P, et al. Helsinki Heart Study: A primary prevention trial of gemfibrozil in middle-aged men with dyslipidemia. Treatment safety, changes in risk factors, and incidence of coronary heart disease. N Eng J Med 1987;317:1237–45.
Google Scholar
Elam M, Lovato L, Ginsberg H. ACCORD Lipid Research: Implications for the Treatment of Dyslipidemia in Type 2 Diabetes. Clinlipidol. 2011;6:9–20.
Google Scholar
Keach A, Sims RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effect of long-term fenofibrate on cardiovascular events in 9795 patients with type 2 diabetes (FIELD study): a randomized controlled trial. Lancet. 2005;366:1849–61.
Google Scholar
Kim MK, Han K, Lee SH. Current trends in big data research using South Korea's national health information database. Diabetes Metatab J. 2022;46:552–63.
Google Scholar
Marx N, Federici M, Schutt K, Müller-Wieland D, Ajan RA, Antunes MJ, et al. 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Eur Heart J. 2023;44:4043–140.
Google Scholar
Kuriki MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW et al Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement by the American Heart Association. circulation. 2021;144:e171-91.
Google Scholar
Pastori D, Falconeni A, Milanese A, Del Sole F, Menichelli D, Hyatt WR Statins and major extremity adverse events in patients with peripheral arterial disease: a systematic review and meta-analysis. Thromb Hemost. 2020;120:866–75.
Google Scholar
Chapman MJ, Ginsburg HN, Amarenko P, Andreotti F, Boren J, Catapano AL, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk for other cardiovascular diseases: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.
Google Scholar
Keating GM, Ormrod D. Micronized fenofibrate: an updated review of clinical efficacy in the management of dyslipidemia. drugs. 2002;62:1909–44.
Google Scholar
Stahls B, Dalongeville J, Orwerks J, Schoonjans K, Reitersdorf E, Furchert JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. circulation. 1998;98:2088–93.
Google Scholar
Brookert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalizes the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993;100:91–102.
Google Scholar
Jin L, Hua H, Ji Y, Jia Z, Peng M, Huang S. Anti-inflammatory effects of fenofibrate in the treatment of diseases. Biomol Biomed. 2023;23:376–91.
Google Scholar
Libby P, Plutzky J. Inflammation in diabetes: the role of peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma agonists. This is J Cardiol. 2007;99:B27–40.
Google Scholar
Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and increase adiponectin levels in patients with primary hypertriglyceridemia. diabetes care. 2005;28:1419–24.
Google Scholar
Herkeles RS, Diamond JR, Poulter C, Danzil S, Nicolaides AN, Mahmoud S, et al. Cardiovascular outcomes in type 2 diabetes. Double-blind, placebo-controlled study of bezafibrate: St Mary's, Northwick Park, Ealing, Diabetes and Cardiovascular Disease Prevention (SENDCAP) study. diabetes care. 1998;21:641–8.
Google Scholar
Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch intern MD. 2002;162:2597–604.
Google Scholar
Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch intern MD. 2005;165:1154–60.
Google Scholar
Group AS, Ginsburg HN, Elam MB, Lovato LC, Krauss JR III, Reiter LA, et al. Effects of lipid combination therapy in type 2 diabetes. N Eng J Med 2010;362:1563–74.
Google Scholar
Zhu L, Hayen A, Bell KJL. Legacy effects of add-on fibrate therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovascular diabetes. 2020;19:28.
Google Scholar
Lee YJ, Song S, Song Y. High-carbohydrate diets and dietary patterns in Koreans and their association with metabolic diseases. Yonsei Med J. 2018;59:834–42.
Google Scholar
Deerochanawong C, Kim SG, Chan YC. The role of fenofibrate use in dyslipidemia and associated comorbidities in Asian populations: a narrative review. Diabetes Metatab J. 2024;48:184–95.
Google Scholar